SXTP 60 DEGREES PHARMACEUTICALS INC

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

WASHINGTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today it will participate in the H.C. Wainwright (HCW) 27th Annual Global Investment Conference at the Lotte New York Palace Hotel, September 8-10, 2025.

Dr. Geoff Dow, CEO, will be presenting live on Wednesday, September 10, at 2:30 ET, and Company management will be conducting 1x1 meetings during the conference. 

Conference attendees are invited to request meetings with management via the conference portal, through their HCW representative, or directly with the Company at the investor contact listed below.

The webcast will be available to watch live, and a replay will be available for approximately 90 days following the presentation on the 60 Degrees Pharmaceuticals investor page, 

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at .

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Media Contact:

Sheila A. Burke



(484) 667-6330

Investor Contact:

Patrick Gaynes



EN
21/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 60 DEGREES PHARMACEUTICALS INC

 PRESS RELEASE

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patien...

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine 90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing FDA-approved treatment for babesiosis WASHINGTON, Nov. 21, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “...

 PRESS RELEASE

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results Q3 2025 net product revenue increased 223% year-over-year to $438 thousandGross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the third fiscal quarter of the 2025 year, ended September 30, 2025. Financial Highlights for the Quarter Ended September 30, 2025: ARAKODA® pharmacy deliveries increased ...

 PRESS RELEASE

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection...

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study Breakthrough Therapy Designation request has been submitted to FDACompany to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)Results obtained using highest sensitivity test available; licensed by FDA for blood donation screeningRemaining enrolled patients will complete the study between January and October 2026Study intended to confirm the high cure rate for tafenoquin...

 PRESS RELEASE

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical...

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competitionA $5K donation from the Company was split between ILADEF and GLA to recognize the winning nameB-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months WASHINGTON, Oct. 09, 2025 (GLOBE NEWSWIRE) --   (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne...

 PRESS RELEASE

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presenta...

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time. Dr. Geoff Dow, 60 Degrees Pharma CEO, will ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch